CVRx (CVRX) Misleading Barostim Sales Growth and Undisclosed Healthcare Fraud Investigation Case
$CVRX investors filed a claim against CVRx, Inc., CEO Kevin Hykes, former CEO Nadim Yared, former CFO Jared Oasheim, and former Chief Revenue Officer Robert John for allegedly misleading investors about Barostim sales growth, concealing problems with its sales team, and failing to disclose potentially illegal marketing practices involving healthcare providers and government insurance programs.
On April 8, 2025, $CVRX fell 46% after reporting disappointing sales and problems with its sales team. On August 7, 2026, the stock plunged another 60%, closing at $2.39 per share, after CVRx lowered its revenue forecast and disclosed a U.S. Department of Justice investigation into its sales and marketing practices.
$CVRX investors can join this case to be notified about potential recovery.
Case Details:
CVRx is a medical device company that develops and sells Barostim, an FDA-approved implantable device designed to improve symptoms in patients with heart failure. The Company relies on its sales representatives to promote Barostim to hospitals and physicians, while helping patients obtain insurance coverage for the treatment.
Throughout the Class Period, CVRx reported growing Barostim sales and told investors that its business expansion, sales team improvements, and patient insurance support programs were driving sustainable revenue growth. According to the lawsuit, these statements concealed ongoing sales problems and potentially improper business practices.
In 2023 and 2024, CVRx highlighted strong revenue growth and expanded its sales organization. Although the Company experienced employee turnover and declining productivity in early 2024, management repeatedly reassured investors that its sales team had stabilized and that newly hired representatives would support future growth.
On April 7, 2025, CVRx reported first-quarter sales of approximately $12.3 million, below expectations. Management acknowledged that many new sales representatives were still developing their territories and that the sales team restructuring had caused greater disruption than anticipated. Following the announcement, $CVRX declined 46% on April 8, 2025.
On May 8, 2025, CVRx disclosed additional problems with its sales organization, including unexpected employee turnover and slower productivity among new hires. The Company lowered its annual revenue forecast from $63–$65 million to $55–$58 million. Following these disclosures, $CVRX fell another 39% on May 9, closing at $4.77 per share.
Despite these setbacks, CVRx continued telling investors throughout 2025 that its sales team was improving, new representatives were becoming more productive, and Barostim adoption was growing.
On August 6, 2026, CVRx lowered its annual revenue forecast again, citing fewer sales territories, weak sales productivity, and difficulties obtaining insurance approvals. Management revealed that approximately 60% of its sales territory managers had joined within the previous 18 months, overwhelming the Company's training and support programs.
That same day, CVRx disclosed that it had received a civil investigative demand from the U.S. Department of Justice on May 14, 2026. The investigation concerned whether the Company had improperly promoted Barostim, offered payments or incentives to healthcare providers, or provided false information to government health insurance programs.
Following these disclosures, $CVRX shares fell 60% on August 7, 2026, declining from $5.94 to $2.39 per share.
Based on these events, $CVRX investors filed a claim against CVRx, alleging the Company:
Misled investors about the success of its sales team restructuring while hiding ongoing employee turnover, inadequate training, and weak sales productivity.
Failed to disclose allegedly improper Barostim marketing practices, potential payments to healthcare providers, and possible false claims submitted to government health insurance programs.
Overstated the strength and sustainability of its revenue growth while understating the financial and legal risks associated with its sales practices and regulatory compliance.
Investors argue that had the truth about CVRx's sales problems, potentially improper marketing practices, and regulatory risks been disclosed, its stock would not have traded at artificially inflated prices during the Class Period of July 25, 2023, through August 6, 2026.